Stock Analysis of Tonix Pharma HLDG Corp. (TNXP)

Loading ...

Birds Eye View of Tonix Pharma HLDG Corp.

Birds's Eye

Technical Analysis of Tonix Pharma HLDG Corp.

Stock Analysis of Tonix Pharma HLDG Corp. (TNXP) - Birds Eye View

1W 2W 1M 3M 1Y 2Y 5Y

Overview

Code	TNXP
Close	0.197
Change	0.0156 / 8.59 %
Volume	7233.75 K
Vol Change	5791.31 K / 401.49 %
Industry	Biotechnology
Sector	Healthcare

AIO Strength Index

Technical Strength	Bullish
Growth Index	Mild Growth
Value Index	Low Value Stock
Profitability Index	Poor Profitability Stock
Stability Index	Low Stability Stock

Fundamental View of Tonix Pharma HLDG Corp.

PE (TTM)

-0.052

Very Poor

Price / Book

0.0449

Excellent

Price / Sales

0.496

Excellent

Piotroski F Score

3.0

Not Good

Market Cap

18841.24 K

Enterprise Value

3074.24 K

All Financial Ratio's

ROA (TTM)

-70.50

Very Poor

ROE (TTM)

-87.00

Very Poor

Net Margin (TTM)

-961.07

Very Poor

Revenue

%

3989.00 K

Net Profit

3.54 %

-121016.00 K

Debt to Equity

0.087

Excellent

Altman Z Score

-2367.93

Very Poor

Quick Ratio

0

Poor

Cash Ratio

1.32

Indecisive

Financial Statement Analysis

Highs/Lows of Tonix Pharma HLDG Corp.

Period	Old price	Stock Return	S&P 500 Returns	High	Low	High Date	Low Date
One Week	0.1717	14.85 %	1.54 %	0.21	0.1707	17-May-24	13-May-24
Two Week	0.1835	7.47 %	3.42 %	0.21	0.1626	17-May-24	08-May-24
One Month	0.1594	23.71 %	5.60 %	0.21	0.149	17-May-24	19-Apr-24
Three Month	0.3815	48.31 %	5.95 %	0.39	0.1202	20-Feb-24	16-Apr-24
Six Months	0.4745	58.44 %	17.48 %	0.6918	0.1202	19-Dec-23	16-Apr-24
One year	1.89	89.57 %	27.52 %	2.0999	0.1202	06-Jun-23	16-Apr-24
Two year	13.8125	98.57 %	29.70 %	9.8125	0.1202	13-Jan-23	16-Apr-24
Five year	3280.0	99.99 %	85.46 %	9.8125	0.1202	13-Jan-23	16-Apr-24
Ten year	1690000.0	100.00 %	182.41 %	3041780.0	0.1202	26-Aug-14	16-Apr-24

Technical View of Tonix Pharma HLDG Corp.

RSI

54.05

Neutral

MACD

-0.0064

Strong Bullish

ADX

27.95

Mild Bullish

Super Trend

0.211

Mild Bearish

Williams %R

-27.00

Neutral

CCI

179.89

Mild Bearish

Technical Analysis Deep Dive

EMA 5

0.186

Strong Bullish

EMA 15

0.181

Bullish

EMA 50

0.220

Mild Bearish

EMA 100

0.320

Mild Bearish

SMA 100

0.283

Mild Bearish

SMA 200

0.476

Strong Bearish

SMA 5 / 20

0.183 / 0.176

Bullish

SMA 15 / 50

0.181 / 0.221

Mild Bearish

SMA 50 / 200

0.221 / 0.476

Mild Bearish

MA Analysis Deep Dive

Charts of Tonix Pharma HLDG Corp.

Returns of Tonix Pharma HLDG Corp. with Peers

Period / Stock	TNXP	APTO	ORGS	TCRT
1 Week	14.85%	-4.07%	-4.79%	-6.45%
1 Mth	23.71%	-6.35%	8.51%	-6.45%
3 Mth	-48.31%	-39.55%	38.05%	-32.16%
6mth	-58.44%	-58.74%	14.80%	14.74%
1 Year	-89.57%	-83.53%	-51.98%	-87.82%
2 Year	-98.57%	-93.16%	-73.95%	-85.13%
5 Years	-99.99%	-96.24%	-87.69%	-98.24%
charts	-

View All Together in Chart Inline Tile

Compare Fundamentals of Tonix Pharma HLDG Corp. with Peers

Ratio / Stock	TNXP	APTO	ORGS	TCRT
PE	-0.052	-0.170	-0.308	-0.565
P/B	0.0449	0.899	1.51	1.20
ROA	-70.50	-210.95	-119.20	-146.34
ROE	-87.00	-529.60	-1117.95	-212.01
Debt To Equity	0.087	-0.136	-1.07	0
Revenue	3989.00 K %	0 %	27753.00 K 22.96 %	15000.00 99.49 %
Net Income	-121016.00 K 3.54 %	-49252.00 K 17.76 %	-25066.00 K 268.35 %	-36456.00 K 3.38 %

Technicals of Tonix Pharma HLDG Corp. with Peers

Technical / Stock	TNXP	APTO	ORGS	TCRT	-
ADX	27.95	29.59	22.73	25.03
CMF	-0.0230	-0.297	-0.144	-0.0193
MFI	72.53	38.29	68.77	27.54
RSI	54.05	38.12	49.51	37.16
MACD Abv Signal	True	True	True	True
Price Above 50 MA	False	False	False	False	-
Price Above 200 MA	False	False	False	False	-

About : Tonix Pharmaceuticals Holding Corp

Address : 26 Main Street, Chatham, NJ, United States, 07928
Tel : 862 799 8599
URL : https://www.tonixpharma.com
Code : TNXP, ISIN : US8902607063, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 10_May_2012
Employee Count : 103

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Note : All Data Generated at the End of Trading Hours (EOD Data)